We upgrade to Buy this morning following a site visit and increasing confidence in the group’s outlook. Over the next twelve months Oxford BioMedica is focused on establishing additional deals with its LentiVector® platform (with the potential to establish another deal with big pharma), progressing technical developments with its LentiVector® platform, reducing its debt profile and spinning out/out-licensing its internal pipeline programmes. There is also upside potential to our forecasts from a ....
05 Dec 2017
N+1 Singer - Oxford BioMedica - Upgrade to Buy as confidence increases
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Oxford BioMedica - Upgrade to Buy as confidence increases
Oxford BioMedica plc (OXB:LON) | 191 1.5 0.4% | Mkt Cap: 191.3m
- Published:
05 Dec 2017 -
Author:
Sheena Berry -
Pages:
3
We upgrade to Buy this morning following a site visit and increasing confidence in the group’s outlook. Over the next twelve months Oxford BioMedica is focused on establishing additional deals with its LentiVector® platform (with the potential to establish another deal with big pharma), progressing technical developments with its LentiVector® platform, reducing its debt profile and spinning out/out-licensing its internal pipeline programmes. There is also upside potential to our forecasts from a ....